DOCSLIB.ORG

Dihydrocodeine 30Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Package leaflet: Information for the patient Dihydrocodeine 30mg tablets This medicine is an opioid, which can cause • have suffered with allergies addiction. You can get withdrawal symptoms if you • have an underactive thyroid gland stop taking it suddenly. • have an enlarged prostate gland and have difficulty urinating and are male Read all of this leaflet carefully before you start • are weak due to illness taking this medicine because it contains important • have adrenal gland insufficiency (symptoms include: low blood information for you. pressure, low blood sugar, muscle weakness, nausea, vomiting, dizziness, skin discolouration, weight loss) • Keep this leaflet. You may need to read it again. • have reduced lung capacity (e.g. asthma or other conditions causing • If you have any further questions, ask your doctor or breathing difficulties) pharmacist. • have a convulsive disorder (suffer from spasms/seizures) • This medicine has been prescribed for you only. Do • have inflammation or blockage in the bowel (symptoms may include not pass it on to others. It may harm them, even if constipation, diarrhoea, abdominal pain/discomfort) their signs of illness are the same as yours. • are or have ever been addicted to opioids, alcohol, prescription • If you get any side effects, talk to your doctor or medicines or illegal drugs • have previously suffered from withdrawal symptoms such as pharmacist. This includes any possible side effects not agitation, anxiety, shaking or sweating, when you have stopped taking listed in this leaflet. See section 4. alcohol or drugs • feel you need to take more Dihydrocodeine tablets to get the same What is in this leaflet level of pain relief, this may mean you are becoming tolerant to the 1 What Dihydrocodeine tablets are and what effects of this medicine or are becoming addicted to it. Speak to your doctor who will discuss your treatment and may change your dose or they are used for switch you to an alternative pain reliever. 2 What you need to know before you take Taking this medicine regularly, particularly for a long time, can lead to Dihydrocodeine tablets addiction. Your doctor should have explained how long you will be taking 3 How to take Dihydrocodeine tablets it for, when it is appropriate to stop and how to do this safely. 4 Possible side effects Rarely, increasing the dose of this medicine can make you more sensitive 5 How to store Dihydrocodeine tablets to pain. If this happens, you need to speak to your doctor about your treatment. 6 Contents of the pack and other information Addiction can cause withdrawal symptoms when you stop taking this 1 What Dihydrocodeine tablets are and what they are medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), used for increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, This medicine has been prescribed for you for relief of moderate to severe shaking, shivering or sweating. Your doctor will discuss with you how to pain, such as: the pain of sciatica (nerve pain of the leg/back), joint and gradually reduce your dose before stopping the medicine. It is important bone pain (osteoarthritis, rheumatoid arthritis and arthritis of the spine), that you do not stop taking the medicine suddenly as you will be more nerve pain, pain following blood vessel disease, cancer or after operations. likely to experience withdrawal symptoms. It contains dihydrocodeine which belongs to a class of medicines called opioids, which are ‘pain relievers’. This medicine has been prescribed for Opioids should only be used by those they are prescribed for. Do not you and should not be given to anyone else. Opioids can cause addiction give your medicine to anyone else. Taking higher doses or more frequent and you may get withdrawal symptoms if you stop taking it suddenly. doses of opioid, may increase the risk of addiction. Overuse and misuse Your doctor should have explained how long you will be taking it for, can lead to overdose and/or death. when it is appropriate to stop and how to do this safely. Children and adolescents Dihydrocodeine tablets are not recommended for children under 12 2 What you need to know before you take years. Dihydrocodeine tablets • Do not take for longer than directed by your prescriber Other medicines and Dihydrocodeine tablets • Taking dihydrocodeine regularly for a long time can lead to addiction, Tell your doctor or pharmacist if you are taking, have recently taken or which might cause you to feel restless and irritable when you stop the might take any other medicines, especially medicines: tablets. • treating allergies (antihistamines) • Taking a painkiller for headaches too often or for too long can make • used to treat sickness (cyclizine, metoclopramide or domperidone) them worse. • to aid sleep (hypnotics) • treating anxiety (anxiolytics) Do not take Dihydrocodeine tablets if you: • treating depression such as monoamine oxidase inhibitors (MAOIs e.g. • are allergic to dihydrocodeine or any of the other ingredients of this moclobemide, linezolid) or tricyclic antidepressants (e.g. amitriptyline) medicine (listed in section 6) • treating mental illness (antipsychotic medicines e.g. chlorpromazine, • have difficulty breathing, or other chronic lung disease haloperidol, sulpiride) • have a head injury or a condition where there is increased pressure • such as mexiletine (used to control heart rhythm) in the skull (may cause painful eyes, change in vision or headache • such as cimetidine (to treat stomach ulcers) behind the eyes) • used in anaesthesia (important if you have recently or are about to • are having an asthma attack receive treatment where an anaesthetic may be used) • are alcohol dependant • used to treat HIV infections (e.g. ritonavir). • are at risk of blocked intestines. Concomitant use of Dihydrocodeine tablets and sedative medicines such Warnings and precautions as benzodiazepines or related drugs increases the risk of drowsiness, Talk to your doctor or pharmacist before taking Dihydrocodeine tablets difficulties in breathing (respiratory depression), coma and may be life- if you: threatening. Because of this, concomitant use should only be considered • have kidney or liver problems when other treatment options are not possible. However, if your doctor • have low blood pressure or are in shock does prescribe Dihydrocodeine tablets together with sedative medicines Continued top of next column Continued over page 148x210 Leaflet Reel Fed Profile (BST) Dihydrocodeine Tablets 30mg x 28, 30, 100 (UK) Dihydrocodeine 30mg Tablets PIL - UK JDE No.: 50999094 approved for print/date Item number: BBBB0939 Colours Non Printing Colours Dimensions: 148x210 (Reel Fed) 1. Black 1. Profile Originator: T. Hull Dimensions: 148x210 Component: Leaflet for Blisters Origination Date: 16.03.2021 Min Body Text Size: 7pt 2. 2. Revision Date: 23/03/2021 Supplier: Accord Barnstaple 3. 3. Pharmacode: 4553 Revised By: C.Grant 4. 5. Proof Round n/a Date Sent: 08/03/21 Technical Date sent: 6. 03 Approval Date received: Technologist: T. Hull [email protected] Technically Approved Cartons and label leaflets only (labels only when specified) German GTIN 14 (incorporating PZN): * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 7 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.02.2020 the dose and duration of concomitant treatment should be limited by your 4 Possible side effects doctor. Tell your doctor about all sedative medicines you are taking and follow Like all medicines, this medicine can cause side effects, although not everybody your doctor’s dose recommendation closely. It could be helpful to inform friends gets them. Please tell your doctor or pharmacist if you notice any of the or relatives to be aware of the signs and symptoms stated above. Contact your following effects or any effects not listed. doctor when experiencing such symptoms. Stop taking Dihydrocodeine tablets and contact your doctor immediately Dihydrocodeine tablets and alcohol or go to your nearest emergency department if you notice the below Alcohol should be avoided whilst taking Dihydrocodeine tablets. serious side effects: Pregnancy and breast-feeding Not known (frequency cannot be estimated from the available data): If you are pregnant or breast-feeding, think you may be pregnant, or are • signs of an allergic reaction such as itchy skin rash, swelling of the face, lips, planning to have a baby, ask your doctor or pharmacist for advice before taking tongue or throat, or difficulty breathing or swallowing this medicine. • hallucinations (seeing or hearing things that are not real), fainting. Do not take Dihydrocodeine tablets if you are pregnant or think you might Other side effects: be pregnant unless you have discussed this with your doctor and the benefits Not known (frequency cannot be estimated from the available data): of treatment are considered to outweigh the potential harm to the baby. If • rash, itchy skin, irregular raised patches, sweating, flushed face you take Dihydrocodeine tablets during pregnancy, your baby may become • drowsiness, changes of mood, confusion, sexual dysfunction, feeling elated dependent and experience withdrawal symptoms after the birth which may • ‘spinning’ sensation, dizziness, headache, ‘pins and needles’, slow and shallow need to be treated. Do not take Dihydrocodeine tablets while you are breathing, muscle rigidity breast-feeding as dihydrocodeine passes into breast milk and will affect your • blurred or double vision, extremely small pupils baby. • slow or fast heart rate, palpitations, low blood pressure Driving and using machines • constipation, feeling or being sick, abdominal pain, dry mouth Dihydrocodeine tablets may reduce your ability to think clearly. Effects such • biliary spasm (causing pain in the right side of your abdomen, particularly as ‘pins and needles’, dizziness, spinning sensations, muscle rigidity, visual after eating a meal, which may spread towards your right shoulder) disturbances, drowsiness, confusion, fainting or hallucinations may occur.
Recommended publications
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products

    Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products

    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
  • 1 Impact of Opioid Agonists on Mental Health in Substitution

    1 Impact of Opioid Agonists on Mental Health in Substitution

    Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trials Supplementary Table 1_ Specific search strategy for each database The following general combination of search terms, Boolean operators, and search fields were used where “*” means that any extension of that word would be considered: Title field [opium OR opiate* OR opioid OR heroin OR medication assisted OR substitution treatment OR maintenance treatment OR methadone OR levomethadone OR buprenorphine OR suboxone OR (morphine AND slow) OR diamorphine OR diacetylmorphine OR dihydrocodeine OR hydromorphone OR opium tincture OR tincture of opium OR methadol OR methadyl OR levomethadyl] AND Title/Abstract field [trial* OR random* OR placebo] AND All fields [depress* OR anxiety OR mental] Wherever this exact combination was not possible, a more inclusive version of the search strategy was considered. Database Search Strategy Ovid for EBM Reviews - Cochrane Central Register of (opium or opiate$ or opioid or heroin or medication Controlled Trials August 2018; Embase 1974 to assisted or substitution treatment or maintenance September 07, 2018; MEDLINE(R) and Epub Ahead treatment or methadone or levomethadone or of Print, In-Process & Other Non-Indexed Citations buprenorphine or suboxone or (morphine and slow) or and Daily 1946 to September 07, 2018 diamorphine or diacetylmorphine or dihydrocodeine or hydromorphone or opium tincture or tincture of opium or methadol or methadyl
  • List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of Narcotic Substances Circulation of Which Is Restricted in Uzbekistan

    List of narcotic substances circulation of which is restricted in Uzbekistan 1. 2C-B(4-bromo-2,5-dimethoxyphenethylamine) 2. 3-methylfentanyl 3. 3-methylthiofentanyl 4. 3-Monoacetylmorphine 5. 4-methylaminorex 6. 6- Monoacetylmorphine 7. Acetorphine 8. Acetyl Dihydrocodeine 9. Acetyl-alfametilfentanil 10. Acetylated opium 11. Acetylcodeine 12. Acetylmethadol 13. Alfametadol 14. Alfatsetilmetadol 15. all fungi that contain Psilocine and Psilocybine 16. Allylprodine 17. Alpha Methylfentanyl 18. Alpha Metiltiofentanil 19. Alphaprodine 20. Anileridin 21. Benzethidine 22. Benzylmorphine 23. Betacetylmethadol 24. Betahydroxyfentanyl 25. Betameprodine 26. Betamethadol 27. Betaprodine 28. Bezitramide 29. Cannabis oil (hashish oil) 30. Cannabis, marihuana 31. Cathine ((+)-norpseudoephedrine) 32. Cathinone (l-alpha-aminopropiofenon) 33. Clonitazene 34. Cocaine 35. Codoxime 36. d- Methadone 37. DB [L-(3,4 - methylenedioxyphenyl) -2 butanamine] 38. Desmethylprodine; MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) 39. Desomorphine 40. DET (N,N-diethyltryptamine) 41. Dexamphetamine 42. Diampromide 43. Diethyl phosphate 44. Diethylthiambutene 45. Dihydromorphine 46. Dimenoxadol 47. Dimepheptanol 48. Dimethylthiambutene 49. Dioxaphetyl butyrate 50. Diphenoxine 51. Dipipanone 52. DMA (2,5-dimethoxyamphetamine) 53. DMGP (dimetilgeptilpiran) 54. DMT (dimethyltryptamine) 55. DOB (d, L-2,5-dimethoxy-4-bromo-amphetamine) 56. DOC (d, L-2,5-dimethoxy-4-chloro-amphetamine) 57. DOET (2,5-dimethoxy-4-ethylamphetamine) 58. Drotebanol 59. Ecgonine 60. Ephedrone 61. Ethylmethylthiambutene 62. Eticyclidine 63. Etonitazene 64. Etorphine 65. Etoxeridine 66. Etryptamine 67. Furethidine 68. Hashish (Anasha, cannabis resin) 69. Heroin (Diacetylmorphine) 70. Hydrocodone 71. Hydrocodone phosphate 72. Hydromorphinol 73. Hydromorphone 74. Isomethadone 75. Ketobemidone 76. Khat 77. L- Methadone 78. Levomethorphan 79. Levomoramide 80. Levophenacylmorphan 81. Levorphanol 82. Lysergic acid and its preparations, that include d-Lysergide (LSD, LSD-25) 83.
  • Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)

    Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)

    NATIONAL DEFENSE RESEARCH INSTITUTE Effects of Medication- Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes A Systematic Review Margaret A. Maglione, Laura Raaen, Christine Chen, Gulrez Shah Azhar, Nima Shahidinia, Mimi Shen, Ervant J. Maksabedian Hernandez, Roberta M. Shanman, Susanne Hempel Prepared for the Office of the Secretary of Defense Approved for public release; distribution unlimited For more information on this publication, visit www.rand.org/t/RR2108 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation R® is a registered trademark. Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Over the past two decades, the U.S. Department of Defense (DoD) has invested unparalleled resources into developing effective treatments for military-related psychological health conditions.
  • Narcotic Drugs Stupefiants Estupefacientes

    Narcotic Drugs Stupefiants Estupefacientes

    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • New Zealand Data Sheet

    New Zealand Data Sheet

    NEW ZEALAND DATA SHEET DHC CONTINUS® 60mg tablets Dihydrocodeine hydrogen tartrate 1 PRODUCT NAME DHC CONTINUS® 60mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dihydrocodeine hydrogen tartrate 60mg equivalent to 40mg dihydrocodeine Excipient(s) with known effect: Lactose anhydrous For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets: White, biconvex, capsule-shaped 12mm in length and 5mm wide, plain on one side and embossed DHC 60 on the other. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications DHC CONTINUS® tablets are recommended for use in the treatment of post-operative pain, and pain associated with cancer. DHC CONTINUS® tablets are also indicated for the treatment of opioid-responsive, chronic severe pain of non-malignant origin, after other conservative methods of analgesia have been tried. It is indicated for use in accordance with the current guidelines on chronic pain management and where there is no psychological contraindication, medicine-seeking behaviour or history of medicine misuse. 4.2 Dose and method of administration Adults and children over 12 years of age: The tablets should be taken at twelve-hourly intervals at a dose of 60-120mg twice daily depending on the severity of the patient’s pain. The maximum recommended dose is 240mg daily since higher doses do not provide any further analgesic effect. Children 12 years or under: Not recommended. Elderly and Special Risk Groups: DHC CONTINUS® tablets should be administered initially at the lowest dose possible in elderly or debilitated patients, patients with impaired renal function, impaired hepatic function, or hypothyroidism. DHC Continus tabs June 2020 Page 1 of 9 NEW ZEALAND DATA SHEET Method of administration: DHC CONTINUS® tablets must be swallowed whole and not broken, chewed or crushed.
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review

    Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review

    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
  • Urine Drug Screening

    Urine Drug Screening

    Urine drug screening Urine drug screens (UDS) are a valuable tool in our management of patients on chronic opioid therapy, however, the results can be misleading and clinical judgment is needed in interpreting results. The basic, initial UDS most clinicians use is usually done by immunoassay. It can identify drugs present in the urine by class (e.g. opioids, benzodiazepines, amphetamines). Immunoassay UDS will give positive results for both a drug being taken and for its metabolites. Codeine, for example, is metabolized to hydrocodone or morphine and then to dihydrocodeine and hydromorphone. Heroin is metabolized to morphine. All of these will be identified as opiates on the basic UDS. Oxycodone is metabolized to oxymorphone; these will be identified as oxycodone on immunoassay UDS. It is therefore important to consider drug metabolism in interpreting UDS test results: hydromorphone may be detected in a patient on morphine hydrocodone may be detected in a patient taking codeine oxymorphone may be the only drug detected in a patient on oxycodone since it is a long lasting metabolite morphine may be the only drug detected in a heroin user. When a basic urine drug screen gives results that do not fit or which cannot be explained, it is a good idea to send the sample for confirmatory testing. This testing is usually done by gas chromatography- mass spectrometry (GC/MS) and will provide more sensitive and specific results. Drug Detection Times (since last use): Drug or Class Detection Time Alcohol 6 - 12 hours Amphetamine or methamphetamine 48 hours Barbiturates, short acting 24 hours Barbiturates, long acting 3 weeks Benzodiazepines, short acting 3 days Benzodiazepines, long acting 30 days Cocaine 2 – 4 days Marijuana, single use 3 days Marijuana, daily use 2 weeks Codeine 48 hours Heroin 2 – 4 days Hydromorphone 2 – 4 days Methadone 3 days Morphine 2 – 3 days Oxycodone 2 – 4 days Detection of drugs can also be affected by other factors.
  • Profiling Hydrocodone and Metabolites in Urine

    Profiling Hydrocodone and Metabolites in Urine

    Profiling Hydrocodone and Metabolites in Urine Charles LoDico, M.S., DABFT June 10, 2014 Drug Testing Advisory Board 2 Publication/Presentation 3 • SOFT 2014 Poster Prescription Opioid Abuse. II. Profiling Hydrocodone and Metabolites in Urine C. P. LoDico*(presenter), R. R. Flegel, R. Heltsley, D. L.Black, J. M.Mitchell, and E. J. Cone • lJAT, Vo 37, October 2013 Prescription Opioids. II. Metabolism and Excertion Patterns of Hydrocodone in Urine Following Controlled Single Dose Administration. E. J. Cone, R. Heltsley, D. L. Black, J. M. Mitchell, C. P. LoDico, and R. Flegel Introduction to Study Design 4 • Hydrocodone (HC) and other semi-synthetic opioids have become commonly misused prescription drugs in the U.S. The combination product, HC with acetaminophen, is the most frequently prescribed opioid drug in the U.S., with more than 136 million prescriptions dispensed in 2011. • Currently , HC is not tested in U.S. federal workplace programs, but there is considerable interest in adding it and other semi-synthetic opiate analgesics (i.e., hydromorphone, oxycodone, oxymorphone) to the test panel because of their widespread abuse and impairing effects. • The objective of this study was to delineate the time course of HC and metabolites in human urine following controlled administration with a single 20 mg oral dose of HC bitartrate Primary Metabolites of Hydrocodone 5 Methods 6 • Subjects: 12 healthy adult volunteers who met the inclusion/exclusion criteria, provided informed consent, had not used opioids in the last 3 months and had not ingested food products containing poppy seeds within the last week. • Dosing: A 20 mg dose of HC bitartrate (two Norco® tablets) with 240 mL of room-temperature water • Urine Collection: Specimens were collected before dosing (baseline [BL]) and as pooled collections from each subject on 3 separate days post- dosing.
  • United States Patent (10) Patent No.: US 8,003,794 B2 Boyd Et Al

    United States Patent (10) Patent No.: US 8,003,794 B2 Boyd Et Al

    USO08003794B2 (12) United States Patent (10) Patent No.: US 8,003,794 B2 Boyd et al. (45) Date of Patent: Aug. 23, 2011 (54) (S)-N-METHYLNALTREXONE 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1, 1984 White et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,430,327 A 2, 1984 Frederickson et al. 4,452,775 A 6, 1984 Kent Howard Wagoner, Warwick, NY (US); 4,457.907. A 7/1984 Porter et al. Suketu P. Sanghvi, Kendall Park, NJ 4.462,839 A 7/1984 McGinley et al. (US); Christopher Verbicky, 4,466,968 A 8, 1984 Bernstein Broadalbin, NY (US); Stephen t St. A s 3. Miley al. Andruski, Clifton Park, NY (US) 4,556,552- - - A 12/1985 Porter2 et al.a. 4,606,909 A 8/1986 Bechgaard et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,615,885 A 10/1986 Nakagame et al. Tarrytown, NY (US) 4,670.287. A 6/1987 Tsuji et al. 4.675, 189 A 6, 1987 Kent et al. (*) Notice: Subject to any disclaimer, the term of this 4,689,332 A 8/1987 McLaughlin et al. patent is extended or adjusted under 35 2.7868 A SE Se U.S.C. 154(b) by 184 days. 4,765,978 A 8/1988 Abidi et al. 4,806,556 A 2/1989 Portoghese (21) Appl. No.: 12/460,507 4,824,853. A 4, 1989 Walls et al. 4,836,212 A 6, 1989 Schmitt et al. (22) Filed: Jul. 20, 2009 4,837.214 A 6, 1989 Tanaka et al.
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)

    ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)

    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000